ArticleBioactive materials2026
A naphthyl polymer with STING-activating property for antigen and adjuvant co-delivery to achieve potent cancer immunotherapy.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic cancer vaccines remain constrained by insufficient intracellular antigen trafficking and weak activation of innate immunity. Here, we report an immunoactive dendrimer-based nanovaccine platform that integrates efficient antigen cytosolic transport with intrinsic stimulation of innate immunity. Through screening a library of thiourea-modified dendrimers, we identify a naphthyl-functionalized polymer (D15) that forms stable antigen nanocomplexes via noncovalent interactions, enabling rapid endosomal escape and efficient cytosolic antigen release in dendritic cells. Mechanistic investigations demonstrated that D15 triggered STING-associated signaling in a cGAS-independent manner, likely related to endosomal membrane perturbation, thereby promoting type I interferon secretion and dendritic cell activation. Owing to its modular structure, D15 also enabled flexible incorporation of additional immunoadjuvants. Incorporation of CpG enhanced lymph node dendritic cell activation and antigen presentation, whereas loading of cGAMP further potentiated STING signaling and intratumoral immune responses. Both CpG- and cGAMP-adjuvanted D15 nanovaccines elicit potent antitumor immune responses in melanoma-bearing mice. Moreover, combination with PD-1 blockade markedly improved tumor suppression, cytotoxic T-cell infiltration, and survival outcomes. Collectively, this work establishes D15 as a multifunctional immunoactive nanocarrier with considerable potential for the construction of next-generation cancer nanovaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.